Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Canada Care Permanently Blocked From Importing Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Company enters into consent decree with FDA and will disgorge $4,000 in profits.

You may also be interested in...



FDA Files Suit Against Canada Care Drugs

FDA has filed suit against Canada Care Drugs for importing drugs into the U.S

Rx Depot Signs Consent Decree Admitting Liability For Importation

The firm and its corporate officers agree to permanently cease operations involving the illegal importation of prescription drugs. Rx Depot has been under a preliminary injunction since November 2003.

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel